Wells Fargo
EVH icon

Wells Fargo’s Evolent Health EVH Stock Holding History

Wells Fargo’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,300
Closed -$196K – 7092
2021
Q2 		$196K Buy
+9,300
New +$186K ﹤0.01% 5041

Other funds holding EVH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo's EVH Position: Q1 2026 in Review

Wells Fargo reduced its Evolent Health (EVH) stake by 63% in Q1 2026, selling an estimated $272K and leaving 50,700 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #5026.

Wells Fargo first reported a position in EVH in Q2 2015 and has held it in 44 quarters since. The position peaked at $20.5M in Q2 2016. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Wells Fargo held 50,700 shares of Evolent Health worth $116K as of Q1 2026.
  • Wells Fargo sold 85,824 Evolent Health shares in Q1 2026, an estimated $272K.
  • Evolent Health made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5026 holding.
  • Wells Fargo first reported a position in Evolent Health in Q2 2015 and has held it in 44 quarters since.
  • Wells Fargo's Evolent Health position peaked at $20.5M in Q2 2016.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.